FIELD: medicine, pharmacy.
SUBSTANCE: this invention relates to the field of biotechnology, particularly to an immunosuppressive agent, and can be used for the treatment of systemic lupus erythematosus (SLE). A peptide is obtained, consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY [SEQ ID NO: 2] in which serine in position 9 is phosphorylated and methionine in position 3 is oxidized or of RIHMVYSKRSGKPRGYAFIEY [SEQ ID NO: 1], in which serine in position 10 is phosphorylated and methionine in position 4 is oxidized.
EFFECT: invention provides peptide or salt thereof, effective in systemic lupus erythematosus treatment.
8 cl, 6 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE COMPOUNDS AND THEIR THERAPEUTIC USE | 2019 |
|
RU2812775C2 |
| ANTI-TAU ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2661111C2 |
| TACI-Fc FUSION PROTEIN AND ITS USE | 2019 |
|
RU2814988C2 |
| TREATING AUTOIMMUNE DISEASES WITH CD154 ANTIBODIES | 2015 |
|
RU2695443C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND APPLICATION METHODS | 2006 |
|
RU2431638C2 |
| TREATMENT OF INFLAMMATION, AUTOIMMUNE, AND NEURODEGENERATIVE DISORDERS WITH IMMUNOSUPPRESSIVE TAT DERIVATIVE POLYPEPTIDES | 2013 |
|
RU2653754C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
| NOVEL SOLUBLE POLYPEPTIDES CD83, COMPOSITIONS AND METHODS OF THEIR APPLICATION | 2009 |
|
RU2535340C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| THYMUS-SPECIFIC PROTEIN | 2005 |
|
RU2535971C2 |
